Drug intelligence / Profile preview

RBM005

Development stage: Preclinical
Lead developer: Ribomic
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

RBM005 is a glycoengineered monoclonal antibody in preclinical development by Rock BioMedical for the treatment of colorectal cancer and head and neck cancer. The drug utilizes a proprietary glycoengineering technology platform to modify antibody glycans, specifically optimizing Fc-related effector functions. This modification is intended to enhance the immune system's ability to kill and clear cancer cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP). While the specific molecular target of the antibody has not been publicly disclosed, the candidate represents Rock BioMedical's core focus on glycan modulation to improve therapeutic outcomes in oncology.

Other names: glycoengineered monoclonal antibody

Beyond the preview

Go deeper on RBM005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBM005.

Explore the full profile